Aptevo Therapeutics, Inc. (APVO)
1.87
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 16:00
1.80
-0.07
(-3.74%)
After-Hours: 18:10
Aptevo Therapeutics Shareholders Equity (Quarterly) : 6.041M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.041M |
| March 31, 2026 | 11.61M |
| December 31, 2025 | 17.38M |
| September 30, 2025 | 17.39M |
| June 30, 2025 | 6.524M |
| March 31, 2025 | -1.473M |
| December 31, 2024 | 4.755M |
| September 30, 2024 | 4.42M |
| June 30, 2024 | 4.463M |
| March 31, 2024 | 6.103M |
| December 31, 2023 | 12.22M |
| September 30, 2023 | 14.72M |
| June 30, 2023 | 16.25M |
| March 31, 2023 | 23.26M |
| December 31, 2022 | 17.97M |
| September 30, 2022 | 15.76M |
| June 30, 2022 | 23.05M |
| March 31, 2022 | -5.884M |
| December 31, 2021 | 1.216M |
| September 30, 2021 | 7.292M |
| June 30, 2021 | 13.88M |
| Date | Value |
|---|---|
| March 31, 2021 | 10.50M |
| December 31, 2020 | 16.59M |
| September 30, 2020 | 2.202M |
| June 30, 2020 | 8.65M |
| March 31, 2020 | 15.15M |
| December 31, 2019 | 11.84M |
| September 30, 2019 | 19.74M |
| June 30, 2019 | 26.20M |
| March 31, 2019 | 39.13M |
| December 31, 2018 | 30.41M |
| September 30, 2018 | 44.00M |
| June 30, 2018 | 56.03M |
| March 31, 2018 | 68.36M |
| December 31, 2017 | 82.04M |
| September 30, 2017 | 90.31M |
| June 30, 2017 | 51.42M |
| March 31, 2017 | 61.49M |
| December 31, 2016 | 50.57M |
| September 30, 2016 | 63.75M |
| June 30, 2016 | 97.20M |
| March 31, 2016 | 89.86M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 14.52M |
| Total Liabilities (Quarterly) | 8.478M |
| Debt to Equity Ratio | 0.6967 |
| Current Ratio | 2.081 |
| Net Debt Paydown Yield | 0.68% |